Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics' stock has been impacted by earnings reports, MolDX engagement, stock offerings, and analyst ratings over the past six months. The company reported its Q1, Q2, and Q3 2025 financial results, with varying EsoGuard test processing numbers and revenue. A MolDX pre-submission meeting was scheduled to review data for EsoGuard coverage. The company strengthened its balance sheet through common stock offerings. Analyst ratings from Needham and Ascendiant Capital maintained a "Buy" recommendation. The share price experienced fluctuations, with a recent decrease despite an overall increase compared to the previous year.

Lucid Diagnostics Inc. tracks seasonality for its stock, with data available to identify mean and median monthly returns to understand seasonal patterns. However, detailed information regarding specific seasonal fluctuations in demand for Lucid Diagnostics' products and services is not publicly available without premium access to financial data.

Lucid Diagnostics, Inc., based in New York, is a commercial-stage medical diagnostics technology company focused on early detection of esophageal precancer and cancer in patients with GERD. Its major products are the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell collection device, which aim to provide a less invasive alternative to endoscopy for early detection.

Lucid Diagnostics Inc. is headquartered in New York, and has expanded its operational presence by launching Lucid Test Centers in various metropolitan areas across the United States, including California, Texas, Florida, and Ohio. The company also operates LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory.

Lucid Diagnostics has received positive recognition for its workplace environment, being named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree. The company maintains a generally positive outlook from analysts, with a consensus rating of "Strong Buy" and a 12-month stock price target of $3.88.

Lucid Diagnostics has a mixed ownership structure, with institutional shareholders owning between 11.53% to 25.53%, insiders owning between 2.41% to 27.19%, and retail investors holding between 47.28% to 77.27%. Major institutional owners include Vanguard Group Inc., Masters Capital Management LLC, and BlackRock, Inc. Pavmed Inc. is the largest individual shareholder, owning 22.74% of the company.